American Journal of Managed Care — The health insurer Cigna has reached agreements with makers of both approved versions of the new cholesterol-fighting class PCSK9 inhibitors, which will align payment with how well patients respond to the drugs. Amgen, which makes evolocumab (Repatha), and Sanofi-Regeneron, sponsor of alirocumab (Praluent), both won FDA approval for this breakthrough therapy class last summer. Both injectable drugs came on the market at costs above $14,000 a year per patient, a level that exceeded analysts’ expectations.